| Date Filed | Type | Description |
| 06/23/2014 |
8-K
| Form 8-K - Current report |
| 06/23/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 06/23/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/19/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 06/19/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/11/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/06/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 06/06/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 05/28/2014 |
SC 13G
| RTW INVESTMENTS, LLC reports a 5.4% stake in Chelsea Therapeutics International Ltd. |
| 05/23/2014 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 05/23/2014 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 05/12/2014 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 05/12/2014 |
8-K
| Other Events |
| 05/09/2014 |
10-Q
| Quarterly Report for the period ended March 31, 2014 |
| 05/08/2014 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 05/08/2014 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 05/08/2014 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 05/08/2014 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits |
| 04/30/2014 |
10-K/A
| Annual Report for the period ended December 31, 2013 [amend] |
| 03/11/2014 |
10-K
| Annual Report for the period ended December 31, 2013 |
| 02/18/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
| 02/14/2014 |
SC 13G/A
| VENROCK HEALTHCARE CAPITAL PARTNERS LP reports a 2.4% stake in CHELSEA THERAPEUTICS INTERNATIONAL, LTD. |
| 02/14/2014 |
SC 13G
| BAKER BROS. ADVISORS LP reports a 8.2% stake in Chelsea Therapeutics International, Ltd. |
| 02/14/2014 |
8-K
| Regulation FD Disclosure |
| 02/03/2014 |
SC 13G/A
| COLUMBIA WANGER ASSET MANAGEMENT LLC reports a |
| 01/30/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/28/2014 |
SC 13G
| BlackRock Inc. reports a 7.2% stake in CHELSEA THERAPEUTICS INTERNATIONAL |
| 01/27/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/21/2013 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 11/15/2013 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement, between Chelsea Therapeutics International, Ltd. and JMP Securities LLC, as representative of the several underwriters named therein",
"Opinion of Morgan, Lewis & Bockius LLP",
"CHELSEA THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK Charlotte, N.C. – November 12, 2013 – Chelsea Therapeutics International, Ltd. , a development stage pharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products, announced today that it plans to offer shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. The Company intends to use the net proceeds from this offering to fund its droxidopa program, including regulatory and possible initial commercialization activity for NORTHERA™, ...",
"CHELSEA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Charlotte, N.C. – November 13, 2013 – Chelsea Therapeutics International, Ltd. , a development stage pharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products, announced today that it has priced an underwritten public offering of 6,666,667 shares of its common stock at an offering price of $3.00 per share, for total gross proceeds of approximately $20 million. The Company has granted the underwriters a 30-day option to purchase up to 1,000,000 additional shares of its common stock to cover over-allotments, if any. The offering is expected to close on November 18, 2013, subject to customary closing conditions. The Company intends to use the net proceeds ..." |
|
| 11/14/2013 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 11/12/2013 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 11/05/2013 |
8-K
| Termination of a Material Definitive Agreement |
| 11/05/2013 |
10-Q
| Quarterly Report for the period ended September 30, 2013 |
|